R S Hare - Publications, H-index & Citations

R S Hare

机构信息待补充

39H指数

112论文数

9.3K被引数

收录论文 23

发表时间

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection

CLINICAL INFECTIOUS DISEASES

IF7.3

2007-02-15

122

OAAI

Skiest, Daniel J.; Vazquez, Jose A.; Anstead, Gregory M.; Graybill, John R.; Reynes, Jacques; Ward, Douglas; Hare, Roberta; Boparai, Navdeep; Isaacs, Randi

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2006-06-01

424

OAAI

Sabatelli, F.; Patel, R.; Mann, P. A.; Mendrick, C. A.; Norris, C. C.; Hare, R.; Loebenberg, D.; Black, T. A.; McNicholas, P. M.

Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions

CLINICAL INFECTIOUS DISEASES

IF7.3

2006-05-15

233

OAAI

Raad, II; Hachem, RY; Herbrecht, R; Graybill, JR; Hare, R; Corcoran, G; Kontoyiannis, DP

Posaconazole as salvage therapy for zygomycosis

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2006-01-01

430

OAAI

Greenberg, RN; Mullane, K; van Burik, JAH; Raad, I; Abzug, MJ; Anstead, G; Herbrecht, R; Langston, A; Marr, KA; Schiller, G; Schuster, M; Wingard, JR; Gonzalez, CE; Revankar, SG; Corcoran, G; Kryscio, RJ; Hare, R

Activity of posaconazole in the treatment of central nervous system fungal infections

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2005-08-31

176

OAAI

Pitisuttithum, P; Negroni, R; Graybill, JR; Bustamante, B; Pappas, P; Chapman, S; Hare, RS; Hardalo, CJ

Posaconazole is a potent inhibitor of sterol 14α-demethylation in yeasts and molds

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2004-10-01

OAAI

Munayyer, HK; Mann, PA; Chau, AS; Yarosh-Tomaine, T; Greene, JR; Hare, RS; Heimark, L; Palermo, RE; Loebenberg, D; McNicholas, PM

Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2004-08-01

OAAI

Patera, AC; Menzel, F; Jackson, C; Brieland, JK; Halpern, J; Hare, R; Cacciapuoti, A; Loebenberg, D

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome p450 14α-demethylase

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2003-02-01

179

OAAI

Mann, PA; Parmegiani, RM; Wei, SQ; Mendrick, CA; Li, X; Loebenberg, D; DiDomenico, B; Hare, RS; Walker, SS; McNicholas, PA

Binding affinities and geometries of various metal ligands in peptide deformylase inhibitors

BIOPHYSICAL CHEMISTRY

IF2.2

2002-12-01

PREAI

Madison, V; Duca, J; Bennett, F; Bohanon, S; Cooper, A; Chu, M; Desai, J; Girijavallabhan, V; Hare, R; Hruza, A; Hendrata, S; Huang, Y; Kravec, C; Malcolm, B; McCormick, J; Miesel, L; Ramanathan, L; Reichert, R; Saksena, A; Wang, J; Weber, PC; Zhu, H; Fischmann, T

Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2001-04-01

490

OAAI

Sulavik, MC; Houseweart, C; Cramer, C; Jiwani, N; Murgolo, N; Greene, J; DiDomenico, B; Shaw, KJ; Miller, GH; Hare, R; Shimer, G

In vitro uptake of SCH 27899 (evernimicin) by rat alveolar macrophages

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2001-03-01

OAAI

Zbaida, S; Brieland, J; Krieter, P; Loebenberg, D; Krishna, G; Horne, D; Lu, XW; Yuan, Y; Hare, R; Cayen, MN; Patrick, JE

Effects of mutations in ribosomal protein L16 on susceptibility and accumulation of evernimicin

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2001-01-01

OAAI

McNicholas, PM; Mann, PA; Najarian, DJ; Miesel, L; Hare, RS; Black, TA

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2001-01-01

217

OAAI

Drusano, GL; Preston, SL; Hardalo, C; Hare, R; Banfield, C; Andes, D; Vesga, O; Craig, WA

Evernimicin (SCH27899) inhibits a novel ribosome target site: Analysis of 23S ribosomal DNA mutants

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2000-11-01

OAAI

Adrian, PV; Mendrick, C; Loebenberg, D; McNicholas, P; Shaw, KJ; Klugman, KP; Hare, RS; Black, TA

In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci: a 24-country study

CLINICAL MICROBIOLOGY AND INFECTION

IF8.5

2000-10-01

OAAI

Goering, R; Nord, CE; Hare, R; Sabatelli, F

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2000-08-01

OAAI

Cacciapuoti, A; Loebenberg, D; Corcoran, E; Menzel, F; Moss, EL; Norris, C; Michalski, M; Raynor, K; Halpern, J; Mendrick, C; Arnold, B; Antonacci, B; Parmegiani, R; Yarosh-Tomaine, T; Miller, GH; Hare, RS

Evernimicin binds exclusively to the 50S ribosomal subunit and inhibits translation in cell-free systems derived from both gram-positive and gram-negative bacteria

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2000-05-01

OAAI

McNicholas, PM; Najarian, DJ; Mann, PA; Hesk, D; Hare, RS; Shaw, KJ; Black, TA

Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2000-03-01

OAAI

Nomeir, AA; Kumari, P; Hilbert, MJ; Gupta, S; Loebenberg, D; Cacciapuoti, A; Hare, R; Miller, GH; Lin, CC; Cayen, MN